You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.
An updated analysis finds the SARS-CoV-2 vaccine from Pfizer and BioNTech to have a 95 percent efficacy.
Early data from Moderna suggests its candidate SARS-CoV-2 vaccine is highly effective, writes the Washington Post.
An initial analysis of early data from Pfizer and BioNTech's COVID-19 vaccine trial indicates it is 90 percent effective, the Washington Post reports.
An FDA advisory panel has determined there isn't enough data to gauge whether a new Alzheimer's disease drug works, according to NPR.
Spectrum reports that a clinical trial of a gene therapy for Angelman syndrome is on hold.
According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.
Two coronavirus vaccine trials that had been paused in the US have resumed.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.
Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.
A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.
In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.